Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520445 | 0.83 | — | — | |
| SCHEMBL2720450 | 0.82 | RAB9A (0.64) | RAB9ANPC1CA1CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28479173 | 0.81 | RAB9A (0.46) | RAB9ANPC1TSHRKDM4EGAA | |
| Ammonia Solution, Strong SCHEMBL28522761 | 0.81 | RAB9A (0.46) | RAB9ANPC1TSHRKDM4EGAA | |
| Hydrochloric Acid SCHEMBL30725878 | 0.81 | RAB9A (0.62) | RAB9ANPC1CA1CA2ALDH1A1 | |
| SCHEMBL2353757 | 0.79 | ALDH1A1 (0.58) | RAB9ANPC1TSHRALDH1A1KDM4E | |
| SCHEMBL10151693 | 0.79 | ALDH1A1 (0.50) | RAB9ANPC1TSHRALDH1A1KDM4E | |
| SCHEMBL6420260 | 0.78 | RAB9A (0.46) | RAB9ANPC1TSHRALDH1A1KDM4E | |
| SCHEMBL2337244 | 0.78 | CA1 (0.70) | RAB9ANPC1TSHRCA1CA2 | |
| SCHEMBL14245491 | 0.78 | RAB9A (0.44) | RAB9ANPC1TSHRKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | TAKAHASHI YOKO | 2010-11-11 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-7781479-B2 | Heteroaryl derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167306-A1 | Novel Heteroaryl Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1837329-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | RAB9A 2398/4885NPC1 1550/4885TSHR 2553/4885 |
| US-20100286144-A1 | HETEROARYL DERIVATIVES | GPR119, SLC2A1, SLC2A4 | RAB9A 1207/4885NPC1 115/4885TSHR 1079/4885 |
| US-20080167306-A1 | Novel Heteroaryl Derivative | GPR119, SLC2A4, SLC5A2 | RAB9A 1362/4885NPC1 108/4885TSHR 1325/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | RAB9A 2817/4885NPC1 1651/4885TSHR 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.